Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Persistent alveolar type 2 dysfunction and lung structural derangement in post-acute COVID-19

View ORCID ProfileAndré F. Rendeiro, View ORCID ProfileHiranmayi Ravichandran, View ORCID ProfileJunbum Kim, View ORCID ProfileAlain C. Borczuk, View ORCID ProfileOlivier Elemento, View ORCID ProfileRobert E. Schwartz
doi: https://doi.org/10.1101/2022.11.28.22282811
André F. Rendeiro
1Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA
2Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA
6CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 14 AKH BT 25.3, 1090, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for André F. Rendeiro
Hiranmayi Ravichandran
2Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA
5Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hiranmayi Ravichandran
Junbum Kim
1Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Junbum Kim
Alain C. Borczuk
3Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
7Northwell Health, Department of Pathology and Laboratory Medicine, Greenvale, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alain C. Borczuk
Olivier Elemento
1Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA
2Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Olivier Elemento
Robert E. Schwartz
4Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert E. Schwartz
  • For correspondence: res2005@med.cornell.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

SARS-CoV-2 infection can manifest as a wide range of respiratory and systemic symptoms well after the acute phase of infection in over 50% of patients. Key questions remain on the long-term effects of infection on tissue pathology in recovered COVID-19 patients. To address these questions we performed multiplexed imaging of post-mortem lung tissue from 12 individuals who died post-acute COVID-19 (PC) and compare them to lung tissue from patients who died during the acute phase of COVID-19, or patients who died with idiopathic pulmonary fibrosis (IPF), and otherwise healthy lung tissue. We find evidence of viral presence in the lung up to 359 days after the acute phase of disease, including in patients with negative nasopharyngeal swab tests. The lung of PC patients are characterized by the accumulation of senescent alveolar type 2 cells, fibrosis with hypervascularization of peribronchial areas and alveolar septa, as the most pronounced pathophysiological features. At the cellular level, lung disease of PC patients, while distinct, shares pathological features with the chronic pulmonary disease of IPF. which may help rationalize interventions for PC patients. Altogether, this study provides an important foundation for the understanding of the long-term effects of SARS-CoV-2 pulmonary infection at the microanatomical, cellular, and molecular level.

Competing Interest Statement

R.E.S. is on the scientific advisory board of Miromatrix Inc and Lime Therapeutics and is a paid consultant and speaker for Alnylam Inc. O.E. is scientific advisor and equity holder in Freenome, Owkin, Volastra Therapeutics and OneThree Biotech. The remaining authors declare no competing financial interests.

Funding Statement

This work was partially supported by the WorldQuant Initiative for Quantitative Prediction. A.F.R. was supported by a NCI T32CA203702 grant. O.E. is supported by Volastra, Janssen and Eli Lilly research grants, NIH grants UL1TR002384 and R01CA194547, and Leukemia and Lymphoma Society SCOR 7012-16, SCOR 7021-20 and SCOR 180078-02 grants. R.E.S. is supported by NIH grants NIAID 2R01AI107301 and NIDDK R01DK121072 and the American Heart Association. R.E.S. is supported as Irma Hirschl Trust Research Award Scholar.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Tissue samples were provided by the Weill Cornell Medicine Department of Pathology using protocols approved by the Tissue Procurement Facility of Weill Cornell Medicine. Experiments using samples from human subjects were conducted in accordance with local regulations and with the approval of the IRB at the Weill Cornell Medicine. The autopsy samples were collected under protocol 20-04021814.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Co-first authors

  • ↵Ω Co-senior authors

Data Availability

Multiplexed imaging data are available at the following publicly available repository: https://doi.org/10.5281/zenodo.7060271. Source code used in data analysis is available at the following publicly available repository: https://github.com/ElementoLab/post-covid-imc

https://doi.org/10.5281/zenodo.7060271

https://github.com/ElementoLab/post-covid-imc

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 29, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Persistent alveolar type 2 dysfunction and lung structural derangement in post-acute COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Persistent alveolar type 2 dysfunction and lung structural derangement in post-acute COVID-19
André F. Rendeiro, Hiranmayi Ravichandran, Junbum Kim, Alain C. Borczuk, Olivier Elemento, Robert E. Schwartz
medRxiv 2022.11.28.22282811; doi: https://doi.org/10.1101/2022.11.28.22282811
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Persistent alveolar type 2 dysfunction and lung structural derangement in post-acute COVID-19
André F. Rendeiro, Hiranmayi Ravichandran, Junbum Kim, Alain C. Borczuk, Olivier Elemento, Robert E. Schwartz
medRxiv 2022.11.28.22282811; doi: https://doi.org/10.1101/2022.11.28.22282811

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (504)
  • Anesthesia (110)
  • Cardiovascular Medicine (1240)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (531)
  • Epidemiology (10023)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2454)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1644)
  • Health Policy (753)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (533)
  • Infectious Diseases (except HIV/AIDS) (11865)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (252)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2281)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1245)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (730)
  • Pharmacology and Therapeutics (313)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4834)
  • Radiology and Imaging (837)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (651)
  • Rheumatology (285)
  • Sexual and Reproductive Health (238)
  • Sports Medicine (227)
  • Surgery (267)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)